One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to KPV in United States. FDA proposal awaiting advisory-committee discussion and final review.

Current source route

KPV in United States

Direct answer / United States

Can you buy KPV in United States?

FDA proposal awaiting advisory-committee discussion and final review

FDA staff proposed not adding KPV free base or KPV acetate to the 503A Bulks List, but PCAC recommended inclusion after reported 8-6-1 votes on both reviewed form questions on July 23, 2026. The advice is nonbinding, does not immediately change the list, and is not FDA approval or a final determination. FDA also states that neither form is a component of an FDA-approved drug and that it found no published human administration study.

  1. 01
    Resolve the nameFDA-reviewed unapproved peptide identity
  2. 02
    Check United StatesCurrent FDA KPV compounding review
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordFDA-reviewed unapproved peptide identity

What KPV resolves to

KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.

Evidence lane
FDA-reviewed unapproved peptide identity
Current record
No FDA-approved KPV drug and no identified human administration study
Checked
July 20, 2026
Lys-Pro-Vallysine-proline-valineMSH 11-13alpha-MSH 11-13KPV peptide
Destination recordCategory-dependent

What United States still has to prove

A national guide to separating state-licensed pharmacy access, federal compounding records, approved-drug information, and laboratory-research listings before comparing price.

Comparison mode
USD / normalized per mg
Price coverage
78 US listings / 20 boards
Guide updated
July 18, 2026
Country-specific evidence found2 records attached to this exact check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail